ReviewFrontiers in immunology2026
Meprin proteases in cutaneous homeostasis and psoriasis: pathophysiological mechanisms and therapeutic prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory disorder characterized by epidermal hyperplasia, barrier dysfunction, and dysregulated crosstalk between keratinocytes and adaptive immune cells. Although the IL-23/IL-17 axis remains central to disease pathogenesis, the extracellular mechanisms that sustain and amplify inflammation are not well defined. Emerging evidence highlights extracellular proteolysis as a critical regulator of inflammatory persistence in psoriatic skin by modulating cytokine bioavailability, receptor activation, extracellular matrix remodeling, and immune cell trafficking, including the release of angiogenic mediators such as VEGF. Zinc-dependent metalloproteases are key contributors to these processes. Among them, meprin α and meprin β exhibit distinct structural and spatial characteristics, positioning them as context-dependent regulators of epithelial and immune homeostasis. In psoriatic lesions, meprin α overexpression results in keratinocyte hyperproliferation, barrier deficiencies with increased transepidermal water loss, and local inflammation due to the proteolytic cleavage of dermokine, an essential regulator of immune responses and epidermal differentiation. Additionally, it is mislocalized to the suprabasal layers. Meprin-α has also been shown to synchronize the activation of skin barrier proteins, effectively contributing to sustained barrier integrity. This, together with the pathogenic repercussions of the meprin-driven pro-inflammatory milieu, has far-reaching implications for this understudied protein. Thus, the current review synthesizes evidence implicating meprins in keratinocyte differentiation, barrier integrity, cytokine processing, and matrix remodeling. We further discuss the regulatory mechanisms that control meprin expression and evaluate its therapeutic potential as an upstream modulator of extracellular inflammatory signaling in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.